Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria
Open Access
- 1 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (11), 1601-1607
- https://doi.org/10.1086/429914
Abstract
Telavancin, a novel lipoglycopeptide, exerts concentration-dependent, rapid bactericidal activity on account of its multiple mechanisms of action. Telavancin is highly active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate, and vancomycin-resistant strains. We conducted a randomized, double-blind, controlled, phase-2 clinical trial. Patients ⩾18 years of age with a diagnosis of complicated skin and soft-tissue infection caused by suspected or confirmed gram-positive organisms were randomized to receive either intravenously administered telavancin once daily or standard therapy (antistaphylococcal penicillin 4 times daily or vancomycin twice daily). For the study, 167 patients were randomized and received at least 1 dose of study medication. Success rates were similar in all analysis populations at the test-of-cure evaluation. Of patients with S. aureus infection at baseline (n = 102), 80% of the telavancin group were cured and 77% of the standard therapy group were cured. For patients with MRSA infection at baseline (n = 48), cure rates were 82% for the telavancin group and 69% for the standard therapy group. Microbiologic eradication in patients with MRSA infection was 84% for the telavancin group versus 74% for the standard therapy group. MIC90 values were lower for telavancin in all tested strains of S. aureus (⩽0.25 ug/mL) compared with the MIC90 values for vancomycin and oxacillin. Similar proportions of patients discontinued therapy for adverse events in both treatment groups (∼5%). Fewer serious adverse events were reported in the telavancin group (4 events) than were for the standard therapy group (9). Clinical and microbiological results of this study support the further development of telavancin, especially for treatment of infection due to MRSA.Keywords
This publication has 14 references indexed in Scilit:
- Trends in Antimicrobial Drug Development: Implications for the FutureClinical Infectious Diseases, 2004
- Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 2004
- Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in PennsylvaniaAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity of TD-6424 against Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- Community‐Acquired Methicillin‐ResistantStaphylococcus aureusInfections in France: Emergence of a Single Clone That Produces Panton‐Valentine LeukocidinClinical Infectious Diseases, 2002
- Epidemiology and Clonality of Community‐Acquired Methicillin‐ResistantStaphylococcus aureusin Minnesota, 1996–1998Clinical Infectious Diseases, 2001
- The Changing Epidemiology of Staphylococcus aureus?Emerging Infectious Diseases, 2001
- Four Pediatric Deaths From Community-Acquired Methicillin-Resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999Published by American Medical Association (AMA) ,1999
- Staphylococcus aureusInfectionsNew England Journal of Medicine, 1998
- Community-Acquired Methicillin-Resistant Staphylococcus aureus in Children With No Identified Predisposing RiskJAMA, 1998